UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000061902 |
|---|---|
| Receipt number | R000067465 |
| Scientific Title | Clinical significance of the Mini Nutritional Assessment-Short Form (MNA-SF) in patients with lung cancer |
| Date of disclosure of the study information | 2026/06/16 |
| Last modified on | 2026/06/14 17:55:26 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Clinical significance of the Mini Nutritional Assessment-Short Form (MNA-SF) in patients with lung cancer
Acronym
Clinical significance of the Mini Nutritional Assessment-Short Form (MNA-SF) in patients with lung cancer
Scientific Title
Clinical significance of the Mini Nutritional Assessment-Short Form (MNA-SF) in patients with lung cancer
Scientific Title:Acronym
Clinical significance of the Mini Nutritional Assessment-Short Form (MNA-SF) in patients with lung cancer
Region
| Japan |
Condition
Condition
lung cancer
Classification by specialty
| Pneumology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To determine whether MNA-SF is a predictor of prognosis in lung cancer patients.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The primary endpoint was the asociation between MNA-SF category and overall survival (OS).
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients with stage IV non-small cell lung cancer (NSCLC) hospitalized between January 1, 2022, and December 31, 2023.
Key exclusion criteria
Patients under the age of 18
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | Chinatsu |
| Middle name | |
| Last name | Nakane |
Organization
Seirei Hamamatsu General Hospital
Division name
Department of Respiratory Medicine
Zip code
430-8558
Address
2-12-12 Sumiyoshi, Chuo Ward, Hamamatsu, Shizuoka Japan
TEL
053-474-2222
c-nakane@sis.seirei.or.jp
Public contact
Name of contact person
| 1st name | Chinatsu |
| Middle name | |
| Last name | Nakane |
Organization
Seirei Hamamatsu General Hospital
Division name
Department of Respiratory Medicine
Zip code
430-8558
Address
2-12-12 Sumiyoshi, Chuo Ward, Hamamatsu, Shizuoka Japan
TEL
053-474-2222
Homepage URL
c-nakane@sis.seirei.or.jp
Sponsor or person
Institute
Seirei Hamamatsu General Hospital
Institute
Department
Personal name
Chinatsu Nakane
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Seirei Hamamatsu General Hospital
Address
2-12-12 Sumiyoshi, Chuo Ward, Hamamatsu, Shizuoka Japan
Tel
053-474-2222
c-nakane@sis.seirei.or.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 06 | Month | 16 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
321
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2025 | Year | 05 | Month | 30 | Day |
Date of IRB
| 2025 | Year | 07 | Month | 18 | Day |
Anticipated trial start date
| 2025 | Year | 06 | Month | 30 | Day |
Last follow-up date
| 2025 | Year | 06 | Month | 30 | Day |
Date of closure to data entry
| 2025 | Year | 07 | Month | 30 | Day |
Date trial data considered complete
| 2025 | Year | 07 | Month | 30 | Day |
Date analysis concluded
| 2026 | Year | 04 | Month | 30 | Day |
Other
Other related information
We extracted the MNA-SF scores, patient demographics, and survival times from patient records and conducted an analysis.
Management information
Registered date
| 2026 | Year | 06 | Month | 14 | Day |
Last modified on
| 2026 | Year | 06 | Month | 14 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000067465
